Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. Am J Med. 1986; 81:765 70. 882. Silber S. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide mononitrate. Eur J Clin Pharmacol. 1990;38 Suppl 1:S35 S51. 883. CV Therapeutics. Ranexa Package Insert. http://www.cvt.com/pdf/ RanexaPI.pdf. 2007. Available at: http://www.cvt.com/pdf/RanexaPI. pdf. Accessed July 15, 2008. 884. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375 82. 885. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non- STelevation acute coronary syndromes: the MERLIN-TIMI 36 ran- domized trial. JAMA. 2007;297:1775 83. 886. Vardeny O, Sweitzer NK, Detry MA, et al. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail. 2009;15:368 73. 887. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 ran- domized trial. Circ Cardiovasc Qual Outcomes. 2008;1:107 15. 888. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119:2032 9. 889. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42 8. 890. Scirica BM, Morrow DA, Hod H, et al. 